Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

KEYNOTE-671 Investigators

doi:10.1016/S0140-6736(24)01756-2

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

KEYNOTE-671 Investigators

Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1240-1252
Number of pages	13
Journal	The Lancet
Volume	404
Issue number	10459
DOIs	https://doi.org/10.1016/S0140-6736(24)01756-2
State	Published - Sep 28 2024

ASJC Scopus Subject Areas

General Medicine

Access to Document

10.1016/S0140-6736(24)01756-2

OpenUrl availability

Full text

Cite this

KEYNOTE-671 Investigators (2024). Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 404(10459), 1240-1252. https://doi.org/10.1016/S0140-6736(24)01756-2

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. / KEYNOTE-671 Investigators.
In: The Lancet, Vol. 404, No. 10459, 28.09.2024, p. 1240-1252.

Research output: Contribution to journal › Article › peer-review

KEYNOTE-671 Investigators 2024, 'Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet, vol. 404, no. 10459, pp. 1240-1252. https://doi.org/10.1016/S0140-6736(24)01756-2

@article{a51bbc241a3440ca8e2000960c673275,

title = "Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial",

author = "{KEYNOTE-671 Investigators} and Spicer, {Jonathan D.} and Garassino, {Marina C.} and Heather Wakelee and Moishe Liberman and Terufumi Kato and Masahiro Tsuboi and Lee, {Se Hoon} and Chen, {Ke Neng} and Christophe Dooms and Margarita Majem and Ekkehard Eigendorff and Martinengo, {Gast{\'o}n L.} and Olivier Bylicki and Delvys Rodr{\'i}guez-Abreu and Chaft, {Jamie E.} and Silvia Novello and Jing Yang and Ashwini Arunachalam and Keller, {Steven M.} and Ayman Samkari and Shugeng Gao and Sergey Afanasyev and Samreen Ahmed and Todd Alekshun and Gustavo Alves and Ian Anderson and Araujo, {Luiz Henrique} and Alexander Arkhipov and Arvind Arora and Jie Bai and Paul Begin and Aleksandr Belonogov and Henri Berard and Radu Berceanu-Ion and {Bernabe Caro}, Reyes and Igor Bondarenko and Reiner Bonnet and {Bosch Barrera}, Joaquim and Carlos Brocca and Maciej Bryl and Alessandra Bulotta and {Calles Blanco}, Antonio and Enric Carcereny and Leticia Carvalho and Cristina Cebotaru and Jamie Chaft and Veena Charu and Fabio Chaves and Jun Chen and Haiquan Chen",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Ltd",

year = "2024",

month = sep,

day = "28",

doi = "10.1016/S0140-6736(24)01756-2",

language = "English",

volume = "404",

pages = "1240--1252",

journal = "The Lancet",

issn = "0140-6736",

number = "10459",

}

TY - JOUR

T1 - Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671)

T2 - a randomised, double-blind, placebo-controlled, phase 3 trial

AU - KEYNOTE-671 Investigators

AU - Spicer, Jonathan D.

AU - Garassino, Marina C.

AU - Wakelee, Heather

AU - Liberman, Moishe

AU - Kato, Terufumi

AU - Tsuboi, Masahiro

AU - Lee, Se Hoon

AU - Chen, Ke Neng

AU - Dooms, Christophe

AU - Majem, Margarita

AU - Eigendorff, Ekkehard

AU - Martinengo, Gastón L.

AU - Bylicki, Olivier

AU - Rodríguez-Abreu, Delvys

AU - Chaft, Jamie E.

AU - Novello, Silvia

AU - Yang, Jing

AU - Arunachalam, Ashwini

AU - Keller, Steven M.

AU - Samkari, Ayman

AU - Gao, Shugeng

AU - Afanasyev, Sergey

AU - Ahmed, Samreen

AU - Alekshun, Todd

AU - Alves, Gustavo

AU - Anderson, Ian

AU - Araujo, Luiz Henrique

AU - Arkhipov, Alexander

AU - Arora, Arvind

AU - Bai, Jie

AU - Begin, Paul

AU - Belonogov, Aleksandr

AU - Berard, Henri

AU - Berceanu-Ion, Radu

AU - Bernabe Caro, Reyes

AU - Bondarenko, Igor

AU - Bonnet, Reiner

AU - Bosch Barrera, Joaquim

AU - Brocca, Carlos

AU - Bryl, Maciej

AU - Bulotta, Alessandra

AU - Calles Blanco, Antonio

AU - Carcereny, Enric

AU - Carvalho, Leticia

AU - Cebotaru, Cristina

AU - Chaft, Jamie

AU - Charu, Veena

AU - Chaves, Fabio

AU - Chen, Jun

AU - Chen, Haiquan

PY - 2024/9/28

Y1 - 2024/9/28

UR - http://www.scopus.com/inward/record.url?scp=85204740664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85204740664&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(24)01756-2

DO - 10.1016/S0140-6736(24)01756-2

M3 - Article

C2 - 39288781

AN - SCOPUS:85204740664

SN - 0140-6736

VL - 404

SP - 1240

EP - 1252

JO - The Lancet

JF - The Lancet

IS - 10459

ER -

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

ASJC Scopus Subject Areas

Access to Document

OpenUrl availability

Other files and links

Cite this